Quidel Q1 Revenues Drop 26 Percent | GenomeWeb

NEW YORK (GenomeWeb) — Quidel said after the close of the market Wednesday that first quarter revenues fell 26 percent to $46.7 million from $62.7 million in Q1 2013.

The decrease in revenue was due to lower sales of infectious disease products in Q1 2014, the result of a weak respiratory disease season.

In Q1, the company generated $18.3 million in total influenza product sales, as a year-over-year decrease in QuickVue Influenza product sales was partially offset by $6.2 million in Sofia Influenza revenue, a 42 percent increase over Q1 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.